Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents

We attempted to clarify the therapeutic capability of antagonists of the farnesoid X receptor (FXR), a nuclear receptor that regulates lipid and bile acid metabolism. Herein, we report the antidyslipidemic effects of a novel synthesized FXR antagonist, compound‐T1, utilizing a dyslipidemic hamster m...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozawa, Emiko, Amano, Yuichiro, Yamakawa, Hiroko, Haba, Megumi, Shimada, Mitsuyuki, Tozawa, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842406/
https://www.ncbi.nlm.nih.gov/pubmed/29541476
http://dx.doi.org/10.1002/prp2.390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842406/
https://www.ncbi.nlm.nih.gov/pubmed/29541476
http://dx.doi.org/10.1002/prp2.390

Ejemplares similares